Da-Yong Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Da-Yong Wang has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Xin-Ying Ji
Department of Nuclear Medicine, Henan International Joint Laboratory for Nuclear Protein Regulation, The First Affiliated Hospital, Henan University College of Medicine, Kaifeng, China
3 shared publications - Dong-Dong Wu
Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, School of Stomatology, Henan University, Kaifeng, China
2 shared publications Ao-Qi Tang
Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, School of Stomatology, Henan University, Kaifeng, China
1 shared publicationDan Lu
Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China
1 shared publicationGuosen Zhang
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Henan University, Kaifeng, China
1 shared publicationHaiqiang Wang
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Henan University, Kaifeng, China
1 shared publication
Latest Publications
- Open Access
- 24 November 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1344
Development of a cancer metastasis-associated risk model via multi-machine-learning algorithms for prognostic risk evaluation and clinical application in oral squamous cell carcinoma
Background: Oral squamous cell carcinoma (OSCC) represents a highly malignant form of cancer characterized by molecular heterogeneity and unsatisfactory treatment outcomes, with approximately 50% of patients experiencing local recurrence and distant metastasis following therapy. Given that metastasis is the most critical determinant of OSCC prognosis, enhancing the precision of clinical interventions and identifying therapeutic targets are of paramount importance. In view of this, this study is the first to develop a machine-learning-based prognostic model integrating epithelial-mesenchymal transition (EMT), anoikis, and basement membrane remodeling genes. Methods: We systematically evaluated 78 algorithm and parameter combinations to identify a robust prognostic model, stratifying patients into High- and Low-risk groups. Kaplan-Meier survival curves and receiver operating characteristic (ROC) analyses were employed to evaluate the predictive performance of this model. Functional enrichment of differentially expressed genes (DEGs) between risk groups revealed key OSCC progression mechanisms. We further analyzed tumor mutation burden, immune microenvironment features, and identified candidate drugs through sensitivity prediction and molecular docking. Results: The identified 13-gene prognostic model effectively stratified patients into high- and low-risk groups, demonstrating strong predictive power for overall survival: the high-risk group exhibited worse prognosis. Mutation landscape demonstrated significant genetic variability within these model genes, which provided insights into the association between elevated tumor mutational burden and adverse prognostic outcomes. Immune landscape revealed a distinct tumor microenvironment: high-risk group exhibited altered immune cell infiltration, along with increased tumor purity, reduced ESTIMATE score and poorer anticipated response to immunotherapy. Finally, seven promising therapeutic candidates were identified through integrated computational drug screening. Conclusion: We developed and validated a 13-gene prognostic model that integrates metastasis-related processes, improves survival prediction, and identifies therapeutic opportunities in OSCC.
- 24 November 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1344
Open AccessDevelopment of a cancer metastasis-associated risk model via multi-machine-learning algorithms for prognostic risk evaluation and clinical application in oral squamous cell carcinoma
Background: Oral squamous cell carcinoma (OSCC) represents a highly malignant form of cancer characterized by molecular heterogeneity and unsatisfactory treatment outcomes, with approximately 50% of patients experiencing local recurrence and distant metastasis following therapy. Given that metastasis is the most critical determinant of OSCC prognosis, enhancing the precision of clinical interventions and identifying therapeutic targets are of paramount importance. In view of this, this study is the first to develop a machine-learning-based prognostic model integrating epithelial-mesenchymal transition (EMT), anoikis, and basement membrane remodeling genes. Methods: We systematically evaluated 78 algorithm and parameter combinations to identify a robust prognostic model, stratifying patients into High- and Low-risk groups. Kaplan-Meier survival curves and receiver operating characteristic (ROC) analyses were employed to evaluate the predictive performance of this model. Functional enrichment of differentially expressed genes (DEGs) between risk groups revealed key OSCC progression mechanisms. We further analyzed tumor mutation burden, immune microenvironment features, and identified candidate drugs through sensitivity prediction and molecular docking. Results: The identified 13-gene prognostic model effectively stratified patients into high- and low-risk groups, demonstrating strong predictive power for overall survival: the high-risk group exhibited worse prognosis. Mutation landscape demonstrated significant genetic variability within these model genes, which provided insights into the association between elevated tumor mutational burden and adverse prognostic outcomes. Immune landscape revealed a distinct tumor microenvironment: high-risk group exhibited altered immune cell infiltration, along with increased tumor purity, reduced ESTIMATE score and poorer anticipated response to immunotherapy. Finally, seven promising therapeutic candidates were identified through integrated computational drug screening. Conclusion: We developed and validated a 13-gene prognostic model that integrates metastasis-related processes, improves survival prediction, and identifies therapeutic opportunities in OSCC.
- 13 March 2025
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 39 (5) , 424-440
Deep learning in nuclear medicine: from imaging to therapy
Background Deep learning, a leading technology in artificial intelligence (AI), has shown remarkable potential in revolutionizing nuclear medicine. Objective This review presents recent advancements in deep learning applications, particularly in nuclear medicine imaging, lesion detection, and radiopharmaceutical therapy. Results Leveraging various neural network architectures, deep learning has significantly enhanced the accuracy of image reconstruction, lesion segmentation, and diagnosis, improving the efficiency of disease detection and treatment planning. The integration of deep learning with functional imaging techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) enable more precise diagnostics, while facilitating the development of personalized treatment strategies. Despite its promising outlook, there are still some limitations and challenges, particularly in model interpretability, generalization across diverse datasets, multimodal data fusion, and the ethical and legal issues faced in its application. Conclusion As technological advancements continue, deep learning is poised to drive substantial changes in nuclear medicine, particularly in the areas of precision healthcare, real-time treatment monitoring, and clinical decision-making. Future research will likely focus on overcoming these challenges and further enhancing model transparency, thus improving clinical applicability.
- 13 March 2025
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 39 (5) , 424-440
Deep learning in nuclear medicine: from imaging to therapy
Background Deep learning, a leading technology in artificial intelligence (AI), has shown remarkable potential in revolutionizing nuclear medicine. Objective This review presents recent advancements in deep learning applications, particularly in nuclear medicine imaging, lesion detection, and radiopharmaceutical therapy. Results Leveraging various neural network architectures, deep learning has significantly enhanced the accuracy of image reconstruction, lesion segmentation, and diagnosis, improving the efficiency of disease detection and treatment planning. The integration of deep learning with functional imaging techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) enable more precise diagnostics, while facilitating the development of personalized treatment strategies. Despite its promising outlook, there are still some limitations and challenges, particularly in model interpretability, generalization across diverse datasets, multimodal data fusion, and the ethical and legal issues faced in its application. Conclusion As technological advancements continue, deep learning is poised to drive substantial changes in nuclear medicine, particularly in the areas of precision healthcare, real-time treatment monitoring, and clinical decision-making. Future research will likely focus on overcoming these challenges and further enhancing model transparency, thus improving clinical applicability.
- 1 December 2024
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 41 (16-18) , 1150-1172
The Emerging Roles of Hydrogen Sulfide in Ferroptosis
Ferroptosis, a form of regulated cell death characterized by a large amount of lipid peroxidation-mediated membrane damage, joins the evolution of multisystem diseases. For instance, neurodegenerative diseases, chronic obstructive pulmonary disease and acute respiratory distress syndrome, osteoporosis and osteoarthritis, and so on. Since being identified as the third gasotransmitter in living organisms, the intricate role of hydrogen sulfide (H2S) in ferroptosis has emerged at the forefront of research. The discovery of novel targets in the relevant metabolic pathways, including transferrin receptor 1, cystine/glutamate antiporter, and others, coupled with the exploration of new signaling pathways, particularly the p53 signaling pathway and the nitric oxide / nuclear factor erythroid 2-related factor 2 signaling pathway, and so on. Many diseases such as emphysema and airway inflammation, myocardial diseases, endothelial dysfunction in aging arteries, and traumatic brain injury have recently been found to be alleviated directly by H2S inhibition of ferroptosis. Safe, effective, and tolerable novel H2S donors have been developed and have shown promising results in phase I clinical trials. Complicated crosstalk between ferroptosis signaling pathway and oncogenic factors results in the risk of cancer when inhibiting ferroptosis. Notably, targeted delivery of H2S is still a challenging task. Discovering more reliable and stable novel H2S donors and achieving their targeted delivery will enable further clinical trials for diseases associated with ferroptosis inhibition by H2S, determining their safety, efficacy, and tolerance.
- 1 December 2024
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 41 (16-18) , 1150-1172
The Emerging Roles of Hydrogen Sulfide in Ferroptosis
Ferroptosis, a form of regulated cell death characterized by a large amount of lipid peroxidation-mediated membrane damage, joins the evolution of multisystem diseases. For instance, neurodegenerative diseases, chronic obstructive pulmonary disease and acute respiratory distress syndrome, osteoporosis and osteoarthritis, and so on. Since being identified as the third gasotransmitter in living organisms, the intricate role of hydrogen sulfide (H2S) in ferroptosis has emerged at the forefront of research. The discovery of novel targets in the relevant metabolic pathways, including transferrin receptor 1, cystine/glutamate antiporter, and others, coupled with the exploration of new signaling pathways, particularly the p53 signaling pathway and the nitric oxide / nuclear factor erythroid 2-related factor 2 signaling pathway, and so on. Many diseases such as emphysema and airway inflammation, myocardial diseases, endothelial dysfunction in aging arteries, and traumatic brain injury have recently been found to be alleviated directly by H2S inhibition of ferroptosis. Safe, effective, and tolerable novel H2S donors have been developed and have shown promising results in phase I clinical trials. Complicated crosstalk between ferroptosis signaling pathway and oncogenic factors results in the risk of cancer when inhibiting ferroptosis. Notably, targeted delivery of H2S is still a challenging task. Discovering more reliable and stable novel H2S donors and achieving their targeted delivery will enable further clinical trials for diseases associated with ferroptosis inhibition by H2S, determining their safety, efficacy, and tolerance.
- Open Access
- 1 January 2022
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 18 (9) , 3605-3620
PCNP is a novel regulator of proliferation, migration, and invasion in human thyroid cancer
Thyroid cancer (TC) has increased globally, with a prominent increase in small, papillary thyroid cancers. PEST-containing nuclear protein (PCNP), a nuclear protein, has been found to be associated with human cancers in recent years. However, the role and molecular mechanism of PCNP in thyroid cancer remain underexplored. In the present study, the results showed that the expression levels of PCNP in human thyroid tissues were higher than those in adjacent non‐tumor tissues. Overexpression of PCNP reduced the proliferation, migration, and invasion of human thyroid cancer cells and down‐regulation of PCNP showed reverse effects. In addition, PCNP regulated cell cycle arrest through modifications in the expression of cell cycle regulating genes and PCNP affected apoptosis via activation of ERK/JNK/p38 pathway in thyroid cancer cells. Moreover, PCNP overexpression promoted autophagy by reducing the expression levels of Wnt/β‐catenin pathway in TC cells, however, PCNP knockdown had opposite effects. Furthermore, PCNP overexpression reduced the growth of xenografted human thyroid cancer, whereas PCNP knockdown showed opposite trends. In conclusion, in vitro and in vivo data demonstrate that PCNP as a tumor suppressor gene may serve as a novel prognostic and potential therapeutic marker in human thyroid cancer.
- 1 January 2022
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 18 (9) , 3605-3620
Open AccessPCNP is a novel regulator of proliferation, migration, and invasion in human thyroid cancer
Thyroid cancer (TC) has increased globally, with a prominent increase in small, papillary thyroid cancers. PEST-containing nuclear protein (PCNP), a nuclear protein, has been found to be associated with human cancers in recent years. However, the role and molecular mechanism of PCNP in thyroid cancer remain underexplored. In the present study, the results showed that the expression levels of PCNP in human thyroid tissues were higher than those in adjacent non‐tumor tissues. Overexpression of PCNP reduced the proliferation, migration, and invasion of human thyroid cancer cells and down‐regulation of PCNP showed reverse effects. In addition, PCNP regulated cell cycle arrest through modifications in the expression of cell cycle regulating genes and PCNP affected apoptosis via activation of ERK/JNK/p38 pathway in thyroid cancer cells. Moreover, PCNP overexpression promoted autophagy by reducing the expression levels of Wnt/β‐catenin pathway in TC cells, however, PCNP knockdown had opposite effects. Furthermore, PCNP overexpression reduced the growth of xenografted human thyroid cancer, whereas PCNP knockdown showed opposite trends. In conclusion, in vitro and in vivo data demonstrate that PCNP as a tumor suppressor gene may serve as a novel prognostic and potential therapeutic marker in human thyroid cancer.
- Open Access
- 11 September 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 639
Distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment
Uterine leiomyosarcoma (ULMS) is an aggressive form of soft tissue tumors. The molecular heterogeneity and pathogenesis of ULMS are not well understood. Expression profiling data were used to determine the possibility and optimal number of ULMS molecular subtypes. Next, clinicopathological characters and molecular pathways were analyzed in each subtype to prospect the clinical applications and progression mechanisms of ULMS. Two distinct molecular subtypes of ULMS were defined based on different gene expression signatures. Subtype I ULMS recapitulated low-grade ULMS, the gene expression pattern of which resembled normal smooth muscle cells, characterized by overexpression of smooth muscle function genes such as LMOD1, SLMAP, MYLK, MYH11. In contrast, subtype II ULMS recapitulated high-grade ULMS with higher tumor weight and invasion rate, and was characterized by overexpression of genes involved in the pathway of epithelial to mesenchymal transition and tumorigenesis, such as CDK6, MAPK13 and HOXA1. We identified two distinct molecular subtypes of ULMS responding differently to chemotherapy treatment. Our findings provide a better understanding of ULMS intrinsic molecular subtypes, and will potentially facilitate the development of subtype-specific diagnosis biomarkers and therapy strategies for these tumors.
- 11 September 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 639
Open AccessDistinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment
Uterine leiomyosarcoma (ULMS) is an aggressive form of soft tissue tumors. The molecular heterogeneity and pathogenesis of ULMS are not well understood. Expression profiling data were used to determine the possibility and optimal number of ULMS molecular subtypes. Next, clinicopathological characters and molecular pathways were analyzed in each subtype to prospect the clinical applications and progression mechanisms of ULMS. Two distinct molecular subtypes of ULMS were defined based on different gene expression signatures. Subtype I ULMS recapitulated low-grade ULMS, the gene expression pattern of which resembled normal smooth muscle cells, characterized by overexpression of smooth muscle function genes such as LMOD1, SLMAP, MYLK, MYH11. In contrast, subtype II ULMS recapitulated high-grade ULMS with higher tumor weight and invasion rate, and was characterized by overexpression of genes involved in the pathway of epithelial to mesenchymal transition and tumorigenesis, such as CDK6, MAPK13 and HOXA1. We identified two distinct molecular subtypes of ULMS responding differently to chemotherapy treatment. Our findings provide a better understanding of ULMS intrinsic molecular subtypes, and will potentially facilitate the development of subtype-specific diagnosis biomarkers and therapy strategies for these tumors.